Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial

A chemopreventive effect of aspirin (ASA) on lung cancer risk is supported by epidemiologic and preclinical studies. We conducted a randomized, double-blinded study in current heavy smokers to compare modulating effects of intermittent versus continuous low-dose ASA on nasal epithelium gene expression and arachidonic acid (ARA) metabolism. Fifty-four participants were randomized to intermittent (ASA 81 mg daily for one week/placebo for one week) or continuous (ASA 81 mg daily) for 12 weeks. Low-dose ASA suppressed urinary prostaglandin E2 metabolite (PGEM; change of −4.55 ± 11.52 from baseline 15.44 ± 13.79 ng/mg creatinine for arms combined, P = 0.02), a surrogate of COX-mediated ARA metabolism, but had minimal effects on nasal gene expression of nasal or bronchial gene-expression signatures associated with smoking, lung cancer, and chronic obstructive pulmonary disease. Suppression of urinary PGEM correlated with favorable changes in a smoking-associated gene signature (P < 0.01). Gene set enrichment analysis (GSEA) showed that ASA intervention led to 1,079 enriched gene sets from the Canonical Pathways within the Molecular Signatures Database. In conclusion, low-dose ASA had minimal effects on known carcinogenesis gene signatures in nasal epithelium of current smokers but results in wide-ranging genomic changes in the nasal epithelium, demonstrating utility of nasal brushings as a surrogate to measure gene-expression responses to chemoprevention. PGEM may serve as a marker for smoking-associated gene-expression changes and systemic inflammation. Future studies should focus on NSAIDs or agent combinations with broader inhibition of pro-inflammatory ARA metabolism to shift gene signatures in an anti-carcinogenic direction.

[1]  E. Ha,et al.  Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer , 2019, JAMA network open.

[2]  N. Cook,et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.

[3]  V. Steele,et al.  Abstract 4983: Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion , 2018, Prevention Research.

[4]  D. Postma,et al.  Nasal gene expression differentiates COPD from controls and overlaps bronchial gene expression , 2017, Respiratory Research.

[5]  S. De Flora,et al.  Early and late effects of aspirin and naproxen on microRNAs in the lung and blood of mice, either unexposed or exposed to cigarette smoke , 2017, Oncotarget.

[6]  Jennifer Beane,et al.  Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression , 2017, Clinical Cancer Research.

[7]  S. De Flora,et al.  Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth. , 2015, Carcinogenesis.

[8]  G. Silvestri,et al.  Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy , 2015, BMC Medical Genomics.

[9]  V. Steele,et al.  Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy , 2015, Cancer Prevention Research.

[10]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[11]  Avrum Spira,et al.  A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. , 2013, American journal of respiratory and critical care medicine.

[12]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[13]  Matthew N. McCall,et al.  fRMA ST: frozen robust multiarray analysis for Affymetrix Exon and Gene ST arrays , 2012, Bioinform..

[14]  Á. Lanas,et al.  Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. , 2012, The American journal of medicine.

[15]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[16]  Avrum Spira,et al.  Characterizing the Impact of Smoking and Lung Cancer on the Airway Transcriptome Using RNA-Seq , 2011, Cancer Prevention Research.

[17]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[18]  Chunyu Liu,et al.  Removing Batch Effects in Analysis of Expression Microarray Data: An Evaluation of Six Batch Adjustment Methods , 2011, PloS one.

[19]  Adam M. Gustafson,et al.  Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.

[20]  P. Sebastiani,et al.  Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. , 2010, Physiological genomics.

[21]  J. Morrow,et al.  Levels of Prostaglandin E Metabolite and Leukotriene E4 Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway , 2009, Cancer Prevention Research.

[22]  E. White,et al.  Association of Nonsteroidal Anti-Inflammatory Drugs with Lung Cancer: Results from a Large Cohort Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[23]  Julie E. Zeskind,et al.  Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium , 2008, BMC Genomics.

[24]  C. Bosetti,et al.  S40. Aspirin and cancer risk: a quantitative review , 2008 .

[25]  Avrum Spira,et al.  Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression , 2007, Genome Biology.

[26]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Morrow,et al.  Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E2, Are Increased in Smokers , 2005, Clinical Cancer Research.

[28]  Li Mao,et al.  Impact of Smoking Cessation on Global Gene Expression in the Bronchial Epithelium of Chronic Smokers , 2005, Cancer Prevention Research.

[29]  J. Morrow,et al.  Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. , 2004, Analytical biochemistry.

[30]  A. Castonguay,et al.  Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. , 1998, Experimental lung research.

[31]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[32]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[33]  Joseph F. Perez-Rogers,et al.  Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection , 2017, Journal of the National Cancer Institute.

[34]  Saini Rk,et al.  Chemopreventive effect of nonsteroidal anti-inflammatory drugs on 9,10-dimethylbenz[a]anthracene-induced lung carcinogenesis in mice. , 2009 .

[35]  Ronald G. Crystal,et al.  Modification of gene expression of the small airway epithelium in response to cigarette smoking , 2008, Journal of Molecular Medicine.